It has been discovered that sleeping pills lower levels of Alzheimer's proteins.

Published Date: 26 Apr 2023

Sleep issues may be a precursor to Alzheimer's disease. Many people who are eventually diagnosed with Alzheimer's have trouble falling and staying asleep years before they develop cognitive issues like memory loss.

Read Full News

Latest News

NeuroVoices: Christina Briscoe, MD; Emily Spelbrink, MD, PhD, on Addressing Equity Gaps in Infantile Epileptic Spasms Syndrome Marco Meglio, Christina Briscoe, MD, Emily Spelbrink, MD, PhD

A pair of pediatric epileptologists highlight the systemic and patient level factors driving inequities in infantile epileptic spasms syndrome care and outline paths toward more equitable diagnosis and treatment.

GLP-1 Liraglutide Displays Effectiveness as Migraine Treatment in Early-Stage Study Louie Pasculli

In a pilot study, liraglutide, a drug used for diabetes and weight-loss, significantly reduced headache days in patients with obesity and chronic or high-frequency migraine, suggesting a potential new preventive therapy.

Fenfluramine Treatment Leads to Long-Term Improved Everyday Executive Functioning in Lennox-Gastaut Syndrome Marco Meglio

A recent analysis reveals fenfluramine's positive effects on executive functioning in adults with Lennox-Gastaut syndrome, independent of seizure reduction.

NeurologyLive®: Charting our 2026 Conference Coverage Louie Pasculli

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

AES Poster Shines Light on Positive Phase 3 GEMZ Study of Fenfluramine in CDKL5 Deficiency Disorder Marco Meglio

Fenfluramine shows significant seizure reduction in CDKL5 deficiency disorder, offering hope for families facing treatment-resistant epilepsy challenges.

Fenfluramine’s Safety Profile Consistent in Long-Term Extension Dravet and Lennox-Gastaut Syndrome Studies Isabella Ciccone, MPH

Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.

Todays Updates

Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial

Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial

Todays Updates

Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial

Combination Navepegritide, Lonapegsomatropin Shows Durable Benefit in Phase 2 Pediatric Achondroplasia Trial

Latest News

A pair of pediatric epileptologists highlight the systemic and patient level factors driving inequities in infantile epileptic spasms syndrome care and outline paths toward more equitable diagnosis and treatment.

In a pilot study, liraglutide, a drug used for diabetes and weight-loss, significantly reduced headache days in patients with obesity and chronic or high-frequency migraine, suggesting a potential new preventive therapy.

A recent analysis reveals fenfluramine's positive effects on executive functioning in adults with Lennox-Gastaut syndrome, independent of seizure reduction.

Follow NeurologyLive's conference journey in 2026, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

Fenfluramine shows significant seizure reduction in CDKL5 deficiency disorder, offering hope for families facing treatment-resistant epilepsy challenges.

Final safety data from an open-label study presented at AES 2025 supported long-term fenfluramine use in pediatric and adult patients with Dravet syndrome or Lennox-Gastaut syndrome.

News All Time

Previewing Parkinson Disease Pipeline: Emerging Trials to Watch in 2026 Marco Meglio

As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Parkinson disease that may impact care.

Previewing Expected FDA Decisions in Neurology for 2026 Marco Meglio

Explore anticipated FDA decisions on groundbreaking neurology drugs in 2026, shaping treatment options for various neurologic conditions.

NeurologyLive® Year in Review 2025: What Trials Could Reshape Alzheimer Care? Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at some of the top ongoing clinical trials in Alzheimer disease and dementia that may impact care.

NeurologyLive® Friday 5 — January 2, 2026 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 2, 2026.

Linking Exercise to Dopamine and Motor Performance in Parkinson Disease Marco Meglio

Margaret Rice, PhD, a professor in the Departments of Neurosurgery and Neuroscience at NYU Grossman School of Medicine, provided answers on recently published preclinical research relating aerobic exercise to dopamine release and coordination in PD.

NeurologyLive® Year in Review 2025: Top Interviews on the AI Takeover Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at our top expert interviews on the latest advances and use of artificial intelligence in neurology care.

NeuroVoices: David A. Hafler, MD, FANA, on Understanding MS as an Autoimmune and Neurodegenerative Disease Isabella Ciccone, MPH, David A. Hafler, MD, FANA

At ECTRIMS 2025, the William S. and Lois Stiles Edgerly Professor of Neurology at Yale School of Medicine discussed evolving insights into the disease pathogenesis of multiple sclerosis.

NeurologyLive® Year in Review 2025: Top trending Migraine Trials NeurologyLive® Staff

As part of NeurologyLive®'s Year in Review 2025, we've compiled some of the top trending migraine trials.

NeurologyLive® Year in Review 2025: Spotlighting SAP Collaborations Isabella Ciccone, MPH

As part of NeurologyLive®'s Year in Review, take a look at our top collaborative interviews with the Strategic Alliance Partnership program in 2025.

NeurologyLive® Year in Review 2025: Most Impactful FDA Decisions Isabella Ciccone, MPH

These were the most impactful FDA approval stories that were part of our coverage in 2025, brought to you as part of NeurologyLive's Year in Review.

Phase 3 REVITALYZ Trial of Once-Nightly Sodium Oxybate in Idiopathic Hypersomnia Finishes Enrollment Marco Meglio

Avadel's REVITALYZ trial for Lumryz in idiopathic hypersomnia shows promise, potentially offering a new treatment option for this underserved condition.

NeurologyLive® Year in Review 2025: Conference Coverage Recap NeurologyLive® Staff

NeurologyLive® provided in-depth coverage of conferences in 2025, highlighting advancements in diagnostics, treatments, and multidisciplinary care across multiple neurological conditions.

NeurologyLive® Brain Games: December 28, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on RBD as a prodromal marker for synucleinopathies!

Wnt/β-catenin in Multiple Sclerosis: A Nuanced Approach to Remyelination Kevin Chang, PharmD

In this Neuropathways piece, Kevin Chang, PharmD, explores the complexities of remyelination in multiple sclerosis and the potential of Wnt/β-catenin signaling as a therapeutic target.

This Week on NeurologyLive® — December 29, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Friday 5 — December 26, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 26, 2025.

Recommended News For You

Modified personalized cancer vaccine generates powerful immune response

Researchers discover that children who survive cancer have socioeconomic challenges.

One CAR T-Cell Therapy for Multiple Myeloma Tops Another in Propensity Matched Study

MCh in Surgical Oncology: Admission, Medical School, Fees, Qualifications Information

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research

AI catches one-third of interval breast cancers missed at screening

Cancer care crowdfunding increasingly common, but rarely successful

Recommended Articles For You

Understanding Blood Dyscrasia: Symptoms, Causes and Treatment Options 

The Role of Alanine Aminotransferase in Liver Health and Disease  

Unraveling the Mysteries of Hematocrit: How It Impacts Your Health 

Artificial Intelligence in Oncology: Current Trends, Challenges and Future Outlook 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC

2.

Should the UK introduce targeted prostate cancer screening? The case for and against

3.

Mobile prostate cancer screening clinic can ID the disease in disadvantaged men

4.

Study Supports Lactated Ringer Solution for Fluid Resuscitation in SCD

5.

Highly Successful Treatment of Lynch Syndrome Patients with PD-1 Inhibitors for Colorectal Cancer.

1.

A New Perspective on Spherocytosis: Uncovering Innovative Treatments

2.

AI on the Front Lines: Revolutionizing Breast Cancer Detection with Artificial Intelligence

3.

Breaking Down the Different Types of Lymphoma: What You Need to Know 

4.

Uncovering the Hidden Signs: How to Recognize the Early Symptoms of Colon Cancer

5.

Unlocking the Mystery of Basilar Artery Stroke: A New Approach to Treatment

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment

2.

Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer

3.

Navigating the Complexities of Ph Negative ALL - Part I

4.

Treatment Paradigm for Patients with R/R Adult B-cell ALL- Expert Discussions

5.

Navigating the Complexities of Ph Negative ALL - Part VII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot